Drug Trial Radar · NCT06923228
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3
Actual
Start
Apr 21, 2025
Primary completion
Jul 30, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- CAGE Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug CGB-500 works to treat atopic dermatitis in subjects 12 years of age or older. It will also learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 decrease the severity of atopic dermatitis on the skin? What medical problems do participants have when taking drug CGB-500? Researchers will compare CGB-500 to a an approved product (1.5% ruxolitinib) to see if CGB-500 works to treat atopic dermatitis. Participants will: Apply CGB-500 and ruxolitinib to different locations on their body twice a day for four weeks. Visit the clinic six times for checkups and tests Keep a diary of their symptoms and when they apply the product
Conditions
- Atopic Dermatitis (AD)
Interventions
CGB-500 Ointment with 1% tofacitinibDrug
experimental drug
Ruxolitinib 1.5% Cream QDDrug
topical cream
Primary outcomes
What the sponsor says the trial is designed to measure.
- evaluate effectivenessTime frame: From enrollment to end of study at 4 weeks
- Safety and tolerabilityTime frame: From enrollment to end of study at 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Dermatology Clinical Research
Fremont, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.